We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 2

1.
FIG. 2.

FIG. 2. From: Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers .

(A) Plasma concentrations of lamivudine after treatment for 4 days with lamivudine at 300 mg once daily alone or in combination with apricitabine at 600 mg twice daily. (B) Concentrations of lamivudine triphosphate in PBMC after treatment for 4 days with lamivudine at 300 mg once daily alone or in combination with apricitabine at 600 mg twice daily.

T. Holdich, et al. Antimicrob Agents Chemother. 2007 August;51(8):2943-2947.
2.
FIG. 1.

FIG. 1. From: Effect of Lamivudine on the Plasma and Intracellular Pharmacokinetics of Apricitabine, a Novel Nucleoside Reverse Transcriptase Inhibitor, in Healthy Volunteers .

(A) Plasma concentrations of apricitabine after oral administration of 600 mg twice daily alone or in combination with lamivudine at 300 mg once daily. Treatment was given for 4 days, and plasma concentrations were measured after the morning dose on day 4. (B) Concentrations of apricitabine triphosphate in PBMC after oral administration of apricitabine, 600 mg twice daily, alone or in combination with lamivudine, 300 mg once daily. Note that because predose samples were not collected for the measurement of apricitabine triphosphate in PBMC, the 24-h samples were assigned to the predose sampling time for analysis.

T. Holdich, et al. Antimicrob Agents Chemother. 2007 August;51(8):2943-2947.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk